Iambic Therapeutics Inc. has disclosed quinazoline compounds acting as cyclin-dependent kinase (CDK) inhibitors, particularly CDK2 and/or CDK4 and/or CDK6 inhibitors reported to be useful for the treatment of ovarian and breast cancer.
Pulsesight Therapeutics SAS has launched with seed financing, with the aim of developing disruptive non-viral gene therapies with minimally invasive delivery technology.
PARP inhibitors such as olaparib are used for the treatment of metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination deficiency (HRD), but a proportion of these patients do not respond to therapy or eventually develop resistance.
Arthex Biotech SL has received FDA clearance to initiate the phase I/IIa Arthemir study of ATX-01 for the treatment of myotonic dystrophy type 1 (DM1).
Researchers from Macquarie University have detailed the discovery of a novel gene therapy vector targeting pathological TAR-binding protein 43 (TDP-43), CTx-1000, as a potential therapeutic candidate for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) – two diseases characterized by cytoplasmic deposition of the nuclear TDP-43.
Derm-Biome Pharmaceuticals Inc. is preparing to initiate IND-enabling studies with DB-007-4, a first-line topical treatment for inflammatory skin diseases, such as acne, atopic dermatitis and rosacea. The company will shortly begin a GLP toxicology study.
Mutations in both KRAS and BRAF oncogenes, which are frequently found in colorectal cancer, are associated with poor prognosis and treatment resistance.
Researchers have identified NIMA-related kinase 1 (NEK1) as a potential therapeutic target driving tumor growth. It was identified using Turbine Ltd.’s Simulated Cell platform when they simulated perturbations in the DNA damage response pathways. NEK1 is involved in DNA damage response, cell cycle and mitosis.
RSS
